Live Attenuated Influenza Virus Vaccines Comprising Microrna Response Elements
AssigneeMount Sinai School of Medicine
InventorBenjamin tenOever
Life of this patent
Estimating the term…
Abstract
The invention is directed to novel live attenuated influenza virus (LAIV) vaccines comprising one or more microRNA (miRNA) Response Element(s) (MRE) within an influenza virus genome. The MREs useful for the present invention can be derived from any miRNA which is highly expressed in influenza-targeted cells of an animal in need of vaccination but are not expressed or are expressed at very low levels in species (e.g., embryonated chicken eggs) or cell lines used for a large-scale vaccine production. This allows efficient vaccine production but renders the vaccine virus susceptible to attenuation in the influenza-targeted cells of vaccinated animals expressing a cognate miRNA.
Claims67
A composition comprising a recombinant influenza virus wherein said influenza virus comprises one or more microRNA Response Element (MRE) sequences.
An isolated nucleic acid molecule comprising an influenza virus coding sequence and one or more microRNA Response Element (MRE) sequences inserted within said coding sequence.
An isolated nucleic acid molecule comprising an influenza virus coding sequence and an artificial 3′ untranslated region (3′ UTR) comprising one or more microRNA Response Element (MRE) sequences inserted between the stop codon of the transcript and the polyadenylation site.
Dependencies are inferred from the claim text.